Metastatic Cancer Clinical Trials in San Francisco, California

5 studies are recruiting for metastatic cancer in San Francisco, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. FOG-001 in Locally Advanced or Metastatic Solid Tumors

   The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, California

   Locations

   33 in total

   Run by

   Parabilis Medicines, Inc.

   See if you can join NCT05919264 on ClinicalTrials.gov

2. Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases

   This is a single-institution, phase 2 trial of zanzalintinib plus investigator-choice bone-strengthening agent in patients with metastatic renal cell carcinoma (RCC) with bone metastases whose disease has advanced on 1-3 prior lines of therapy, including at least one immune oncology-based (IO) ther…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of California, San Francisco, San Francisco, California

   Run by

   Kelly Fitzgerald, MD

   See if you can join NCT07043608 on ClinicalTrials.gov

3. (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

   This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll approximately 482 patients. Part 1 consists of two evaluations: 1) confirming the dose of an updated formulation of CGT9486 to be used in subsequent …

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of California, San Francisco, San Francisco, California

   Locations

   126 in total

   Run by

   Cogent Biosciences, Inc.

   See if you can join NCT05208047 on ClinicalTrials.gov

4. Imaging of Solid Tumors Using FAP-2286

   This is a multi-arm prospective trial that evaluates the ability of a novel imaging radiolabeled agents to detect metastatic cancer in participants with solid tumors using a gallium 68 (68Ga-) or copper 64 (64Cu-) FAP-2286 tracer. FAP-2286 is a peptidomimetic molecule that that binds to Fibroblast …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California, San Francisco, San Francisco, California

   Run by

   Thomas Hope

   See if you can join NCT04621435 on ClinicalTrials.gov

5. Comparison of Whole Body DWI to FDG PET

   This is a single arm prospective trial that evaluates whole body diffusion weight imaging (DWI) compared to 18F-fludeoxyglucose (FDG) Positron Emission Tomography with Magnetic resonance imaging (PET/MRI) in participants with known metastatic cancer.

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of California, San Francisco, San Francisco, California

   Run by

   University of California, San Francisco

   See if you can join NCT06630845 on ClinicalTrials.gov